Syros Pharmaceuticals, Inc. (SYRS)
SYRS moved a median of +0.51% 30 minutes after news, and -0.31% by the close. How SYRS actually reacts to news — the realized, point-in-time move the market made, measured across 307 labeled events over the last three years with zero look-ahead.
SYRS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 49% | 300 |
| 30-min | +0.51% | 55% | 307 |
| 60-min | +0.29% | 55% | 307 |
| to close | -0.31% | 45% | 307 |
| Middle 50% of SYRS reactions | -1.16% to +3.10% |
|---|---|
| Median reaction (30-min) | +0.51% |
| Measured reactions | 307 |
Half of all Syros Pharmaceuticals, Inc. news events land between -1.16% and +3.10% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How SYRS reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 14 | -4.00% | 29% | -7.96% |
| Coverage initiations | 24 | -0.04% | 46% | +1.40% |
| Rating reiterations | 21 | -0.39% | 43% | -1.56% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how SYRS ranks against every other measured name →
That’s how SYRS usually reacts — get an email when it moves on news →Email me when SYRS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SYRS's baseline. Nothing else.
Recent SYRS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials | Press release | PR Newswire | +4.98% | +3.73% | |
| Form 15-12G Syros Pharmaceuticals, | SEC filing · Form 15-12G | SEC EDGAR | +13.70% | -10.35% | |
| Form EFFECT Syros Pharmaceuticals, | SEC filing · Form EFFECT | SEC EDGAR | -9.05% | -19.81% | |
| Form 25 Syros Pharmaceuticals, | SEC filing · Form 25 | SEC EDGAR | +32.93% | -9.33% | |
| Form POS AM Syros Pharmaceuticals, | SEC filing · Form POS | SEC EDGAR | +32.93% | -9.33% | |
| Form S-8 POS Syros Pharmaceuticals, | SEC filing · Form S-8 | SEC EDGAR | +32.93% | -9.33% | |
| Form 8-K Syros Pharmaceuticals, For: Feb 28 | SEC filing · Form 8-K | SEC EDGAR | -3.41% | +1.29% | |
| Form 8-K Syros Pharmaceuticals, For: Feb 28 | SEC filing · Form 8-K | SEC EDGAR | +6.79% | +13.57% | |
| Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration | Press release | Business Wire | +6.79% | +13.57% | |
| Form 8-K Syros Pharmaceuticals, For: Jan 06 | SEC filing · Form 8-K | SEC EDGAR | +1.51% | +6.38% | |
| Form 8-K Syros Pharmaceuticals, For: Dec 04 | SEC filing · Form 8-K | SEC EDGAR | -0.09% | +3.67% | |
| Form 8-K Syros Pharmaceuticals, For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | -9.26% | -23.33% | |
| Form 8-K Syros Pharmaceuticals, For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | -11.21% | -9.57% | |
| Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression | Press release | Business Wire | -11.21% | -9.57% | |
| Form 10-Q Syros Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.19% | -0.40% | |
| Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update | Press release | Business Wire | -1.19% | -0.40% | |
| Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024 | Press release | Business Wire | +2.88% | -8.41% | |
| Bronstein, Gewirtz and Grossman, LLC Is Investigating Syros Pharmaceuticals, Inc. (SYRS) And Encourages Shareholders to Connect | Press release | Accesswire | +2.42% | -1.96% | |
| Bronstein, Gewirtz and Grossman, LLC Is Investigating Syros Pharmaceuticals, Inc. (SYRS) And Encourages Stockholders to Connect | Press release | Accesswire | -0.65% | -2.26% | |
| Form 8-K Syros Pharmaceuticals, For: Sep 04 | SEC filing · Form 8-K | SEC EDGAR | +1.97% | +0.66% | |
| Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings | Press release | GlobeNewswire | +0.32% | -4.11% | |
| Bronstein, Gewirtz and Grossman, LLC Initiates an Investigation into Allegations Against Syros Pharmaceuticals, Inc. (SYRS) And Encourages Stockholders to Reach Out | Press release | Accesswire | +1.30% | -0.65% | |
| Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings | Press release | Business Wire | +1.97% | +0.66% | |
| Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Against Syros Pharmaceuticals, Inc. (SYRS) and Encourages Stockholders to Seek Compensation for Alleged Wrongdoings | Press release | Accesswire | -0.54% | -7.13% | |
| Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged | Press release | PR Newswire | +0.00% | -0.65% | |
| Bronstein, Gewirtz and Grossman, LLC Encourages Syros Pharmaceuticals, Inc. (SYRS) Investors to Inquire about Securities Investigation | Press release | Accesswire | +1.88% | -3.13% | |
| Bronstein, Gewirtz and Grossman, LLC Encourages Syros Pharmaceuticals, Inc. (SYRS) Shareholders to Inquire about Securities Investigation | Press release | Accesswire | -0.59% | -2.38% | |
| Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings | Press release | GlobeNewswire | +1.88% | -3.13% | |
| Bronstein, Gewirtz and Grossman, LLC Encourages Syros Pharmaceuticals, Inc. (SYRS) Stockholders to Inquire about Securities Investigation | Press release | Accesswire | +0.62% | +2.47% | |
| Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Against Syros Pharmaceuticals, Inc. (SYRS) and Encourages Shareholders to Seek Compensation for Alleged Wrongdoings | Press release | Accesswire | +0.59% | -7.65% | |
| Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences | Press release | Business Wire | +0.00% | -5.99% | |
| Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings | Press release | Business Wire | +1.64% | +0.00% | |
| Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged | Press release | PR Newswire | -1.79% | -0.59% | |
| Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings | Press release | GlobeNewswire | -1.79% | -0.59% | |
| Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Stockholders to Seek Compensation for Alleged Wrongdoings | Press release | Accesswire | -1.79% | -0.59% | |
| Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings | Press release | Accesswire | -1.79% | -0.59% | |
| Form 8-K Syros Pharmaceuticals, For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +4.87% | +3.78% | |
| Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial | Press release | Business Wire | +4.87% | +3.78% | |
| Form 10-Q Syros Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.77% | -7.55% | |
| Form S-8 Syros Pharmaceuticals, | SEC filing · Form S-8 | SEC EDGAR | -0.77% | -7.55% | |
| Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update | Press release | Business Wire | -0.77% | -7.55% | |
| Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024 | Press release | Business Wire | +0.00% | -4.92% | |
| Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression | Press release | Business Wire | +0.00% | +8.82% | |
| Form 8-K Syros Pharmaceuticals, For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.91% | |
| Form 10-Q Syros Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +3.52% | +6.05% | |
| Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update | Press release | Business Wire | +3.52% | +6.05% | |
| Syros to Participate in Upcoming Investor Conferences | Press release | Business Wire | +0.00% | +1.78% | |
| Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024 | Press release | Business Wire | +0.00% | +1.78% | |
| Form ARS Syros Pharmaceuticals, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | +3.21% | |
| Form DEF 14A Syros Pharmaceuticals, For: Jun 05 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +3.21% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SYRS section they belong to.
Where else SYRS is measured.
SYRS earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Galectin Therapeutics Inc. (GALT) | 309 | 0.00% | 50% |
| MENLO THERAPEUTICS INC COMMON (MNLO) | 308 | 0.00% | 49% |
| Adverum Biotechnologies, Inc. (ADVM) | 306 | 0.00% | 49% |
| Establishment Labs Holdings Inc. - Common Shares (ESTA) | 306 | +0.13% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Syros Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled SYRS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 307 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 55% of SYRS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SYRS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.